I
n the United States, HIV-associated nephropathy (HIVAN) affects approximately 1% of the overall HIV-1-seropositive population and has become the third most common cause of renal failure in adult black men (1, 2) . A component of the disease process is the direct infection of renal parenchymal cells, including all tubular, parietal, and visceral epithelial cell types (3) . The pathology of HIVAN thus is largely typified by epithelial cell defects and includes both a glomerular lesion (collapsing focal segmental glomerulosclerosis [FSGS] ) and an equally profound tubulointerstitial lesion that involves all segments of the nephron (4, 5) . Previous investigations characterizing these epithelial cell defects have shown that the cells undergo a dedifferentiation that includes changes in the expression level and pattern of cell differentiation markers and increased rates of proliferation (6, 7) . There also is a well-described increase in apoptotic cell death, which has been documented in human kidney biopsies, in kidneys from animal models of HIVAN, and with in vitro infections of cultured renal epithelial cells (6 -12) .
In general, a pathologic role for apoptotic cell death has been described in many forms of chronic and acute renal diseases and in transplant rejection. The most common mechanism of apoptosis implicated in the kidney is mediated by Fas (CD95) and Fas ligand (FasL; CD178) interactions. Many renal cell types normally express Fas and FasL, and renal expression of these proteins can be upregulated in response to various disease processes (13) . In HIVAN, a previous report by Conaldi et al. (9) presented evidence for Fas upregulation during HIV-1 infection of cultured proximal tubular epithelial cells and suggested a role for Fas-mediated apoptosis in the tubular damage of HIVAN.
It was shown previously that the transcription of the genes for Fas (14 -16) and FasL (17) (18) (19) are regulated by NF-B, an inducible transcription factor complex with a principal role in mediating immune and inflammatory processes (20) . NF-B also has a central role in regulating apoptosis. Initially, NF-B was believed to be exclusively an antiapoptotic factor primarily on the basis of the analysis of several NF-B null (knockout) transgenic mice. This is clearly the case in the development and homeostasis of the immune system; however, this is not a universal observation for all cell types or signaling events. It has become increasingly more evident that NF-B can have both antiapoptotic and proapoptotic functions, depending on the stimulus, cell type, and differentiation state (21) . The proapoptotic functions of NF-B are associated with its ability to increase the expression of well-known proapoptotic genes, such as Fas and FasL, and also possibly through mechanisms that repress antiapoptotic gene expression (22) .
In HIV-1-infected immune cells, NF-B is a necessary host transcription factor that is required for both elongation of initial, Tat-independent viral transcripts and producing the high levels of Tat-dependent viral gene expression needed for productive infection (23) . It also has been shown in chronically infected immune cells that NF-B is altered to a "persistently activated" state, thus ensuring the abundant expression of the viral genes (24) . Similar to infected immune cells, we showed previously that HIV-1 gene expression in the kidney is also dependent on NF-B transactivation (25) , and we have new evidence that suggests that NF-B is similarly dysregulated to a persistently activated state in HIV-1-expressing kidney cells (Bruggeman, unpublished observations) .
Here we present evidence that links the altered NF-B transactivation with renal epithelial cell apoptosis, a component of the pathogenic process in HIVAN. Using the HIV-1 transgenic mouse model and human biopsy specimens, we found that the expression of Fas and FasL was elevated in diseased kidneys in both glomerular and tubular cells. Because FasL expression is a crucial step leading to activation of the Fas pathway, we investigated the mechanism of FasL upregulation in HIV-1-expressing renal epithelial cells. Using conditionally immortalized podocyte cell lines from the HIV-1 transgenic mouse model, we observed elevated levels of Fas and FasL mRNA and protein in podocytes. This enhanced level of FasL mRNA in HIVAN podocytes could be reduced with treatment of an NF-B inhibitor, and we further demonstrated the role of NF-B by showing its direct binding to the FasL promoter in vivo, as well as elevated FasL promoter activity in HIVAN podocytes. These data suggest that the HIV-induced activation of NF-B is associated with de novo FasL expression and subsequent podocyte apoptosis and thus may contribute to the glomerular lesion in HIVAN.
Materials and Methods

Mouse Model, Cell Lines, and Plasmids
The HIV-1 transgenic mouse model develops a renal disease very similar to human HIVAN and has been described in detail (26, 27) . The podocyte cell lines that are derived from this mouse model also have been described previously and include both transgenic podocytes isolated from a heterozygous adult mouse ("HIVAN podocytes") and normal podocytes prepared from a normal littermate (28) . The cell lines, conditionally immortalized with a temperature-sensitive SV40 T antigen, were propagated under permissive conditions and used for experiments after growth for 8 to 10 d at nonpermissive conditions as described previously (29) . The soluble peptide inhibitor for NF-B SN50 and control peptide SN50M were purchased from BIOMOL (Plymouth Meeting, PA) and used at 0.1 mg/ml. SN50 inhibits all p50-containing NF-B and can have broad effects on NF-B activation because multiple NF-Bs contain p50.
A FasL promoter reporter plasmid (pFasLTAL-secreted alkaline 
Immunohistochemistry and Western Blotting
Immunohistochemistry of human and mouse kidney sections was performed as described previously (5) . Fas (M-20) and FasL (N-20) antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) were used at 1:200 dilution and detected with an avidin-biotin-based system (Vectastain ABC elite kit; Vector Laboratories, Burlingame, CA) with horseradish peroxidase-driven chromagen production (AEC substrate; Vector Laboratories). HIV-1 transgenic mouse kidneys and human tissue were formalin-fixed and embedded in paraffin. Human biopsies and normal human nephrectomy tissue were obtained in accordance with all requirements of the Mount Sinai Medical Center and Columbia University Medical Center Institutional Review Boards. All animal studies were conducted in accordance with the animal care and use requirements of Case Western Reserve University.
Western blotting was performed on whole-cell extracts using the protocol provided by the primary antibody manufacturer using the above Fas and FasL antibodies (1:1000 dilution). Secondary antibodies (1:1000 dilution) were horseradish peroxidase-conjugated goat antirabbit (Jackson ImmunoResearch, West Grove, PA), and detection was by luminescence (ECL; Amersham Biosciences, Piscataway, NJ) according to the manufacturer's instructions.
Apoptosis Assays
Apoptosis detection in cell cultures was determined with a colorimetric assay for caspase-8 activity (ApoAlert; Clontech) used according to the manufacturer's instructions with 10 6 cells. Apoptotic cells also were quantified using a fluorescence nuclear dye method as described previously (31) . Data are presented as percentage of DAPI-enhanced late apoptotic nuclei per total nuclei in randomly selected high-power fields. Fas apoptosis was induced using a cross-linking anti-Fas antibody (Jo2; Pharmingen, San Diego, CA) at 5 g/ml for 4 h. An antiFasL antibody (Pharmingen) was used at 10 g/ml for a 16-h pretreatment.
Reverse Transcription-PCR and Quantitative PCR
For reverse transcription, RNA from podocyte cell lines was extracted using TRIzol (Invitrogen, Carlsbad, CA), and 1 g of total cellular RNA was used for synthesis of cDNA (SuperScript II; Invitrogen) using random priming. For standard PCR, amplification conditions and primers for murine Fas and FasL coding regions were as described previously (32) . For semiquantitative PCR using standard PCR amplification conditions, a range of dilutions of input cDNA template were amplified for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) to determine the amount of cDNA needed to visualize linear amplification of products resolved on agarose gels. This linear range of input cDNA (equivalent for GAPDH amplification between samples) subsequently was used for amplification of Fas and FasL. Primer pairs that were used for semiquantitative PCR for NF-B target genes were as follows: Mouse IL-6 forward TAGTCCTTCCTAC-CCCAATTTCC and reverse TTGGTCCTTAGCCACTCCTTC, and mouse NF-B p50 forward GGAGGCATGTTCGGTAGTGG and reverse CCCTGCGTTGGATTTCGTG. For quantitative (real-time) PCR (LightCycler FastStart DNA Master SYBR Green I; Roche), relative quantification with external standards (GAPDH) and analysis with the second derivative maximum method were used. Data are presented as the absolute number of mRNA copies. Quantitative PCR primers for murine FasL were forward CATCACAACCACTCCCACTG and reverse GTTCTGCCAGTTCCTTCTGC (GenBank accession no. S76752). Quantitative PCR amplification conditions were as follows: for FasL, melt at 96°C for 10 s, anneal at 68°C for 5 s, extend at 72°C for 10 s; and for GAPDH (primers purchased from Clontech), melt at 96°C for 10 s, anneal at 60°C for 5 s, and extend at 72°C for 10 s, all for 45 cycles.
Chromatin Immunoprecipitation Assay
The chromatin immunoprecipitation (ChIP) assay was performed using a kit from Upstate Biotechnologies (Lake Placid, NY) with the following modifications. Formaldehyde cross-linking was stopped with 125 mM glycine for 5 min at room temperature. After reversal of cross-links, eluates were precipitated overnight at Ϫ20°C with 2.5 vol of ethanol. Precipitated material was resuspended in 100 l of TE and digested with 0.2 mg/ml proteinase K and 0.1 mg/ml DNase-free RNase A for 1 h at 45°C. DNA was purified using a QiaQuick spin column (Qiagen, Valencia, CA) and eluted with 30 l of kit elution buffer, with 3 l of the purified DNA used for PCR. An antibody against p65 (RelA c-19; Santa Cruz Biotechnology) was used to immunoprecipitate NF-B-containing chromatin. PCR primers for the murine FasL promoter were derived from available sequence (GenBank accession no. AF045739) and were forward ACAGGCCTCTCAGGA-CACAC and reverse TAAGGTTTCCGCAGTCAAGG. These primers flank the only functional NF-B site in the mouse promoter as previously identified (19) . Positive control primers were for the IB␣ promoter and have been described (33) . Standard PCR (30 cycles) was performed with AmpliTaq Gold (Applied Biosystems, Foster City, CA) using the manufacturer's recommended conditions with an annealing temperature of 50°C.
Statistical Analyses
All graphed data represent three independent experiments performed in triplicate. Data are presented as the average Ϯ SD with probability determined by t test (two-tailed, two-sample equal variance).
Results
A possible role for Fas-mediated apoptosis in HIVAN has been suggested from in vitro infections of cultured tubular epithelial cells (9) . To further this observation, we studied the in vivo expression pattern of Fas and FasL in human biopsy specimens and kidneys from the HIV-1 transgenic mouse model. In HIVAN biopsies, both cystic tubules and sclerosed glomeruli expressed abundant levels of Fas and FasL in comparison with normal nephrectomy tissue (Figure 1) . In serial sections, it seemed that the same epithelium expressed both Fas and FasL, suggesting concurrent expression of both proteins. In comparison with both collapsing and noncollapsing idiopathic FSGS, the most abundant glomerular expression of Fas and FasL was observed in HIVAN. The most abundant tubular expression, Figure 1 . Fas and Fas ligand (FasL) expression in HIV-associated nephropathy (HIVAN), collapsing and noncollapsing idiopathic focal segmental glomerulosclerosis (FSGS) biopsies, and normal nephrectomy tissue. Serial sections are shown for all except normal tissue. In HIVAN, immunolocalization for Fas and FasL expression appeared in similar areas of tubular epithelium (arrowheads), and expression of both proteins was abundant in glomeruli in a podocyte distribution. In collapsing idiopathic FSGS, staining for Fas and FasL could be detected in focal areas of glomerular epithelial cell hyperplasia (arrows) but at qualitatively lower levels as compared with HIVAN. In noncollapsing idiopathic FSGS, abundant expression of especially Fas was observed in tubules; however, the expression level in glomeruli was low in comparison. Expression in normal tissue was low for Fas and undetectable for FasL.
however, was seen in noncollapsing FSGS, which would be consistent with a recent report by Erkan et al. (34) . In glomeruli of both collapsing and noncollapsing idiopathic FSGS, focal areas of faint Fas staining were observed. This Fas expression co-localized with faint staining for FasL in collapsing idiopathic FSGS, whereas very little glomerular FasL expression was detected in noncollapsing FSGS.
In the HIV-1 transgenic mouse model, the expression and distribution of Fas and FasL were compared between normal and diseased transgenic mouse kidneys (Figure 2 ). Similar to the human biopsies, cystic tubules and collapsed glomeruli had clearly elevated levels of Fas and FasL as compared with normal mouse kidney tissue. The glomerular expression seemed to be associated with podocytes, the glomerular cell type previously shown to be infected in the human disease and also the glomerular cell type that expresses the transgene in our mouse model. Thus, the cell types that express the HIV-1 genome are also the cells with evidence of elevated expression of Fas and FasL.
To investigate this role of Fas-mediated apoptosis in HIVAN, we used podocyte cell lines that were established from normal and HIV-1 transgenic mice. With the use of a standard method to verify the mechanism of apoptosis involved in the Fas pathway, cultured podocytes were incubated with a Fas crosslinking antibody that artificially provides a stimulus to activate the Fas pathway. The induction of apoptosis was monitored both by caspase 8 activity and with a nuclear dye to detect both live and dead cells (Figure 3) . By quantification of the number of pyknotic nuclei, there was a significantly higher basal level of apoptosis in HIVAN cells as compared with normal (approximately four-fold), which is consistent with previously reported apoptotic rates in HIV-1-infected podocytes (31) . In addition, a statistically significant increase in the number of apoptotic cells in both cell types was observed with the addition of a crosslinking anti-Fas antibody ( Figure 3B ). Similarly, the basal level of caspase activity was significantly higher in the HIVAN podocytes as compared with normal ( Figure 3C ), suggesting the HIVAN podocytes have an existing caspase 8 stimulus that is absent or reduced in normal podocytes. Treatment with a standard dose (5 g/ml) of the anti-Fas antibody similarly increased caspase activity in both cell types ( Figure 3C) ; however, the maximal level of assayable caspase 8 activity was lower in the HIVAN cells at this dose and treatment interval. Preliminary survey experiments indicated that the normal and HIVAN cells responded differently depending on the dose and the length of treatment with the anti-Fas antibody. The HIVAN cells generated more caspase 8 activity at lower doses of antiFas, likely as a result of the higher expression of Fas (see below), and had less total caspase activity with longer treatment periods, likely reflecting the complete decomposition of apoptotic cells that died early in the treatment period that were missed by the end point assay (data not shown). These studies indicated that Fas is functionally expressed on both normal and HIVAN cells and that activation of the Fas pathway is at least one mechanism of apoptosis in podocytes. The anti-Fas antibody treatments also induced cell death as determined by the nuclear dye assay, which monitors the loss of plasma membrane integrity. This indicates that the increased caspase 8 activity is representative of later apoptotic events and cell death.
Because the immunohistochemistry results indicated that the levels of Fas and FasL are increased in vivo, the steady-state mRNA levels of Fas and FasL were compared between normal and HIVAN podocytes. Using semiquantitative reverse transcription-PCR technique ( Figure 4A ), both normal and HIVAN podocytes expressed Fas, and the level of Fas expression in the HIVAN podocyte was increased (approximately 10-fold) over normal. With this technique, however, there was no detectable basal expression of FasL in normal podocytes, but abundant expression was detected in HIVAN podocytes. This suggests that HIV-1 may induce de novo expression of FasL in podocytes. The mRNA level for both genes paralleled the protein expression levels as detected by Western blotting ( Figure 4B) . Thus, the composite of these studies with both human and mouse tissues and cells have consistently shown that in the setting of HIV-1 gene expression, Fas and FasL expression is elevated in renal epithelial cells. The observation that FasL expression was detected only in HIVAN podocytes may provide an explana- . FasL staining (E and F) was also very intense in the HIV-1 transgenic kidneys and was seen in dilated tubules and in a collapsed glomerulus (arrowhead). Sections were counterstained with hematoxylin. tion for the higher basal level of apoptosis detected by the caspase assays in Figure 3 . In addition, because mRNA levels were elevated, it would be logical that a transcriptional event plays a fundamental role in the observed increased expression.
We showed recently that HIV-1 expression in renal epithelial cells, similar to infected leukocytes, causes a persistent or constitutive activation of NF-B (Bruggeman, unpublished observations). Previous studies have shown that the promoter for the FasL gene (human and mouse) contains functional NF-B binding sites that are critical to its transcriptional regulation. Thus, these observations suggest a possible connection between the HIV-induced NF-B activation and the increased FasL gene expression. To demonstrate functionally a role for NF-B in FasL gene expression, we transfected normal and HIVAN podocytes with the pFasLTAL-SEAP reporter plasmid to measure FasL promoter activity ( Figure 5A ). In these transfections, the transcriptional activity of the FasL promoter was found to be higher in HIVAN podocytes as compared with normal podocytes. The basal promoter activity of the pTAL-SEAP reporter plasmid alone was 6673 Ϯ 116 relative light units/10 5 cells and was not statistically different from the level of expression of the pFasLTAL-SEAP plasmid in normal podocytes. Thus, similar to the Northern and Western blots in Figure 4 , essentially no expression of the FasL promoter was observed in normal podocytes. In addition, co-transfection of the pFasLTAL-SEAP with a constitutively expressed dominant negative IB␣, a strong inhibitor of NF-B, resulted in reduced FasL promoter activity in the HIVAN cells. These studies suggest that NF-B activation induces FasL expression in HIVAN podocytes and that suppression of NF-B can reduce expression to the level seen in normal podocytes. To demonstrate further NF-B's role in FasL expression, we treated HIVAN podocytes with a soluble peptide inhibitor of NF-B that blocks the ability of an activated NF-B complex to bind target DNA sequences ( Figure 5B ). RNA was harvested and the expression of FasL mRNA was assayed by quantitative (real-time) PCR. Blocking NF-B suppressed the HIV-1-induced increase in FasL expression in HIVAN podocytes by 10-fold, whereas a control treatment had no effect. Cell viability was lower for the SN50-treated cells, but FasL expression in all samples was normalized to GAPDH expression. The effect of NF-B activity on FasL expression seemed to be a direct transcriptional regulation of the FasL gene as determined by ChIP assays, a method that identifies in vivo DNA-protein interactions. ChIP assays ( Figure 5C ) were performed in HIVAN podocytes using an antibody against p65 (RelA), the transactivating subunit of the NF-B complex. The ChIP assay showed that RelA bound the FasL promoter within a defined region that contains the functional NF-B site. These studies demonstrate that an NF-B RelA-containing complex directly bound the FasL promoter in vivo and suggest that the status of NF-B activation directly correlates with the level of FasL mRNA. The direct association of HIV-1-induced NF-B activation and FasL gene expression suggests a mechanism for increased Fas-mediated apoptosis in HIVAN through the renal epithelial cell production of FasL.
It was shown recently that Fas/FasL signaling, in addition to its well-known role in regulating apoptosis, may have additional, apoptosis-independent functions, such as participating in fibrosis and inflammation (35) . With NF-B's central role in mediating inflammatory processes, it is possible that FasL signaling may be activating NF-B in podocytes, as has been shown to occur in other cell types and some cancers (36 -38) . To exclude the possibility that the observed increases in NF-B activation were in response to Fas/FasL signaling and not an HIV-1-induced event, we treated HIVAN podocytes with a neutralizing anti-FasL antibody ( Figure 5D ). After treatment, RNA was harvested and the expression level of three NF-B target genes (IL-6, FasL, and NF-B p50) was quantified to determine whether the treatment changed the expression level. The mRNA half-life for IL-6 is approximately 1 to 3 h (39). Because no change was observed in NF-B target gene expression with this treatment, it suggests that Fas signaling is not making a significant contribution to the NF-B activation state in HIVAN podocytes.
Discussion
During innate and acquired immune responses, many cells undergo apoptosis in response to viral infection. This results in the elimination of infected cells with a consequent reduction in the release of progeny virus. This protective response, however, comes at a high cost to the host, as abnormal apoptosis contributes to tissue destruction and pathogenesis. This is no more evident than during HIV-1 infection, in which the devastating effect on the immune system is due to the apoptotic killing of T helper lymphocytes (40, 41) . These cells are destroyed by both cytotoxic T lymphocyte-mediated killing of infected cells and also to a greater extent the killing of uninfected (bystander) cells via activation-induced cell death, a normal homeostatic process of the immune system mediated by Fas. HIV-1-induced apoptosis contributes to pathology in other organ systems as well, including cardiomyocyte cell death in HIV-1 cardiomyopathy and in central nervous system cell death, which contributes to AIDS dementia complex and HIV-induced encephalopathy (42) (43) (44) . Similar to studies presented here, Ghorpade et al. (45) also implicated NF-B-induced FasL expression as the likely mechanism of astrocyte cell death in AIDS dementia. This may suggest that HIV-induced Fas-mediated apoptosis is a common mechanism of cell death in nonlymphoid cell types and underscores the importance of the Fas pathway in host pathogenesis.
Our studies have centered on the HIV-induced NF-B activation and its contribution to host cell dysfunction, such as the apoptotic defect in HIVAN. Although NF-B has more wellknown activities in protecting cells from apoptosis, it can also induce apoptosis through the upregulation of proapoptotic genes such as Fas and FasL. The ability of one transcription factor to participate in such mutually exclusive functions as being both proapoptotic and antiapoptotic stems from the fact that NF-B is not a single transcription factor with one mechanism of activation. NF-B is a multiprotein complex that is composed of either homo-or heterodimers of DNA binding subunits and transactivating subunits, which are bound by an inhibitor, IB. Multiple genes code for these subunits, and 11 unique NF-B dimers have been confirmed in vivo (20) . The highly important IB phosphorylation events occur through a multiprotein kinase complex that is known to participate in numerous signal transduction cascades (46) . Cells typically express many NF-B subunit proteins, and we have found that cultured podocytes express at least seven. Thus, the combinational diversity and multiple activation mechanisms of the NF-B pathway even in a single cell type such as the podocyte is extraordinarily complex. It is possible that NF-B activation in one setting could promote apoptosis and in another setting suppress apoptosis and would depend on the varied aspect of the NF-B activation cascade, including the initiating stimulus and the composition of the NF-B complex and its affinity for target gene enhancers.
That NF-B can induce the expression of both Fas and FasL in one cell establishes a mechanism whereby FasL does not need to be supplied in trans via an immune cell or through the circulation. This dual expression of both Fas and FasL by epithelial cells seems to have a specific role in the immune response to many viral, bacterial, and parasitic infections. A study that investigated cytotoxic bacterial infections in the lung also found that the airway epithelial cells dually expressed both Fas and FasL to induce apoptosis (47) . With the use of bone marrow reconstitution experiments using lpr (Fas-deficient) and gld (FasL-deficient) mutant mice, the apoptotic process was shown to be mediated exclusively by the Fas and FasL expressed by the epithelial cells and did not involve any contribution of FasL from the immune system. In the absence of this apoptotic response, all animals developed a lethal systemic infection. It was suggested that this mechanism inherent in lung epithelia was a critical innate immune response to limit the infection to a local area and prevent systemic spread. Thus, it may be possible that this increase in Fas-mediated apoptosis observed in HIVAN may be an intrinsic, first-line defense mechanism of renal epithelia in response to the infection or the presence of viral proteins.
Alternatively, this higher rate of apoptosis may reflect the abnormally high rate of proliferation also characteristic of HIVAN. Mechanisms that control proliferation and apoptosis share common cell-cycle regulatory proteins, and events that activate proliferation can also activate apoptosis (48) . In the setting of a high proliferation rate, increased apoptosis is believed to function as a brake to delimit the maximal rate of proliferation and control tissue size (49) . However, in HIVAN, even with an elevated apoptotic rate, the level of proliferation remains out of balance, resulting in a net increase in the overall size of the kidney, including podocyte hypertrophy, hyperplasia, and pseudocrescent formation. Therefore, a connection between apoptosis and proliferation in HIVAN may exist but likely represents a complicated relationship of varied aspects of host-virus interactions. One possible connection between these pathologic processes is the HIV-induced activation of NF-B. Constitutive NF-B activation has emerged as a hallmark of malignant transformation in lymphomas and solid organ tumors through the upregulation of cyclin D1, and it has been shown that the proliferative defect in HIVAN podocytes is a cyclin D1-dependent cell cycle progression (50, 51) . Thus, many aspects of HIVAN pathogenesis are likely to center on the dysregulation of NF-B induced by the virus.
Whether the increased apoptosis in HIVAN is a compensatory mechanism in the setting of increased proliferation or an innate antiviral mechanism in the renal epithelial cells is currently under investigation. In either case, identification of the mechanism of NF-B activation will be important in understanding HIVAN pathogenesis. This mechanism may involve specific effects of individual viral proteins' interfering with signal transduction cascades that activate NF-B-specific kinases. Recent studies have made a strong case for Nef as the likely candidate protein in the proliferative and dedifferentiation aspects of HIVAN pathogenesis (52, 53) . Alternatively NF-B activation may result from systemic oxidative stress responses that are known to occur during HIV-1 infection (54). Reactive oxygen species can act as second messengers for activating NF-B, released either systemically from activated immune cells in a general inflammatory process or through intracellular events that involve interactions with host redoxregulating molecules and individual viral proteins (55) . With a better understanding of the role of specific viral proteins, as well as key host responses such as NF-B activation, it may be possible to identify novel and specific targets for the treatment of HIVAN.
